XK
MDGL icon

Xact Kapitalforvaltning’s Madrigal Pharmaceuticals MDGL Stock Holding History

Xact Kapitalforvaltning’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,300
Closed -$278K – 1512
2018
Q3 		$278K Hold
1,300
– – 0.01% 1408
2018
Q2 		$364K Buy
+1,300
New +$228K 0.01% 1188

Other funds holding MDGL

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Xact Kapitalforvaltning's MDGL Position: Q4 2018 in Review

Xact Kapitalforvaltning sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2018, closing a stake of 1,300 shares — an estimated $278K sold.

Xact Kapitalforvaltning first reported a position in MDGL in Q2 2018 and held it in 2 quarters. The position peaked at $364K in Q2 2018. 136 funds tracked by Wall St. Rank hold MDGL as of Q4 2018.

  • Xact Kapitalforvaltning reported no remaining Madrigal Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Xact Kapitalforvaltning sold 1,300 Madrigal Pharmaceuticals shares in Q4 2018, an estimated $278K.
  • Xact Kapitalforvaltning first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Xact Kapitalforvaltning's Madrigal Pharmaceuticals position peaked at $364K in Q2 2018.
  • 136 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2018.

Based on Xact Kapitalforvaltning's 13F filing for Q4 2018, filed 31 Jan 2019.